These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 27569924)
1. Treatment Response and Outcomes in Post-transplantation Lymphoproliferative Disease vs Lymphoma in Immunocompetent Patients. Trusson R; Serre JE; Szwarc I; Brunot V; Garrigue V; Delmas S; Kanouni T; Cartron G; Mourad G Transplant Proc; 2016; 48(6):1927-33. PubMed ID: 27569924 [TBL] [Abstract][Full Text] [Related]
2. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340 [TBL] [Abstract][Full Text] [Related]
3. Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients. Francis A; Johnson DW; Craig J; Teixeira-Pinto A; Wong G Kidney Int; 2018 Oct; 94(4):809-817. PubMed ID: 30173897 [TBL] [Abstract][Full Text] [Related]
4. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ; Homan van der Heide JJ; Veeger NJ; Kluin PM; Kluin-Nelemans HC Clin Transplant; 2005 Jun; 19(3):327-34. PubMed ID: 15877793 [TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation. Yoon JH; Lee S; Kim HJ; Lee JW; Min WS; Chung BH; Yang CW; Kim YS; Kim JI; Moon IS; Oh EJ; Park GS; Cho SG Transpl Int; 2014 Jul; 27(7):721-32. PubMed ID: 24684689 [TBL] [Abstract][Full Text] [Related]
6. Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders. Rosenberg AS; Ruthazer R; Paulus JK; Kent DM; Evens AM; Klein AK Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):684-692.e3. PubMed ID: 27771291 [TBL] [Abstract][Full Text] [Related]
7. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. Caillard S; Porcher R; Provot F; Dantal J; Choquet S; Durrbach A; Morelon E; Moal V; Janbon B; Alamartine E; Pouteil Noble C; Morel D; Kamar N; Buchler M; Mamzer MF; Peraldi MN; Hiesse C; Renoult E; Toupance O; Rerolle JP; Delmas S; Lang P; Lebranchu Y; Heng AE; Rebibou JM; Mousson C; Glotz D; Rivalan J; Thierry A; Etienne I; Moal MC; Albano L; Subra JF; Ouali N; Westeel PF; Delahousse M; Genin R; Hurault de Ligny B; Moulin B J Clin Oncol; 2013 Apr; 31(10):1302-9. PubMed ID: 23423742 [TBL] [Abstract][Full Text] [Related]
8. Human leukocyte antigen type and posttransplant lymphoproliferative disorder. Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163 [TBL] [Abstract][Full Text] [Related]
9. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients. Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821 [TBL] [Abstract][Full Text] [Related]
10. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience. Wasson S; Zafar MN; Best J; Reddy HK J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222 [TBL] [Abstract][Full Text] [Related]
12. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases]. Chen DB; Wang Y; Song QJ; Shen DH Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829 [TBL] [Abstract][Full Text] [Related]
13. Early onset post transplantation lymphoproliferative disorders: analysis of international data from 5 studies. Khedmat H; Taheri S Ann Transplant; 2009; 14(3):74-7. PubMed ID: 19644164 [TBL] [Abstract][Full Text] [Related]
14. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality. Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147 [TBL] [Abstract][Full Text] [Related]
15. Characteristics and prognosis of post-transplant lymphoproliferative disorders within renal allograft: Report from the PTLD.Int. Survey. Khedmat H; Taheri S Ann Transplant; 2010; 15(3):80-6. PubMed ID: 20877272 [TBL] [Abstract][Full Text] [Related]
16. Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival. Rosenberg AS; Klein AK; Ruthazer R; Evens AM Am J Hematol; 2016 Jun; 91(6):560-5. PubMed ID: 26928381 [TBL] [Abstract][Full Text] [Related]
17. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562 [TBL] [Abstract][Full Text] [Related]